Genomic instability and copy-number heterogeneity of chromosome 19q, including the kallikrein locus, in ovarian carcinomas

Molecular Oncology

Volumn 5, Issue 1, 2011, Pages 48-60

  Bayani, Jane ^a,b   Marrano, Paula ^c   Graham, Cassandra ^a,c   Zheng, Yingye ^d   Li, Lin ^d   Katsaros, Dionyssios ^e   Lassus, Heini ^f   Butzow, Ralf ^f   Squire, Jeremy A ^g   Diamandis, Eleftherios P ^a,b,h  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d Fred Hutchinson Cancer Research Center   (United States)

^e UNIVERSITY OF TURIN   (Italy)

^f UNIVERSITY OF HELSINKI   (Finland)

^g QUEEN S UNIVERSITY   (Canada)

^h UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Chromosomal instability; Copy number; FISH; Kallikrein locus; Ovarian carcinoma; Structural rearrangement

Indexed keywords

FORMALDEHYDE; KALLIKREIN 6; PARAFFIN;

ADULT; AGGRESSIVENESS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CHROMOSOME 19Q; CHROMOSOME STRUCTURE; CONTROLLED STUDY; COPY NUMBER VARIATION; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DOSAGE; GENE FREQUENCY; GENE LOCUS; GENE OVEREXPRESSION; GENE REARRANGEMENT; GENETIC HETEROGENEITY; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; NUMERICAL CHROMOSOME ABERRATION; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; STRUCTURAL CHROMOSOME ABERRATION; UNIVARIATE ANALYSIS;

OXALIS TUBEROSA;

EID: 78951493324     PISSN: 15747891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molonc.2010.08.002     Document Type: Article

References (86)

1. Al-Romaih K., Bayani J., Vorobyova J., Karaskova J., Park P.C., Zielenska M., Squire J.A. Chromosomal instability in osteosarcoma and its association with centrosome abnormalities. Cancer Genet. Cytogenet. 2003, 144:91-99.
2. Barbarotto E., Schmittgen T.D., Calin G.A. Micrornas and cancer: profile, profile, profile. Int. J. Cancer 2008, 122:969-977.
3. Bast R.C., Hennessy B., Mills G.B. The biology of ovarian cancer: new opportunities for translation. Nat. Rev. Cancer 2009, 9:415-428.
4. Bayani J., Brenton J.D., Macgregor P.F., Beheshti B., Albert M., Nallainathan D., Karaskova J., Rosen B., Murphy J., Laframboise S., Zanke B., Squire J.A. Parallel analysis of sporadic primary ovarian carcinomas by spectral karyotyping, comparative genomic hybridization, and expression microarrays. Cancer Res. 2002, 62:3466-3476.
5. Bayani J., Paderova J., Murphy J., Rosen B., Zielenska M., Squire J.A. Distinct patterns of structural and numerical chromosomal instability characterize sporadic ovarian cancer. Neoplasia 2008, 10:1057-1065.
6. Bayani J., Paliouras M., Planque C., Shan S.J., Graham C., Squire J.A., Diamandis E.P. Impact of cytogenetic and genomic aberrations of the kallikrein locus in ovarian cancer. Mol. Oncol. 2008, 2:250-260.
7. Bayani J., Selvarajah S., Maire G., Vukovic B., Al-Romaih K., Zielenska M., Squire J.A. Genomic mechanisms and measurement of structural and numerical instability in cancer cells. Semin. Cancer Biol. 2007, 17:5-18.
8. Bayani J., Squire J. Multi-color fish techniques. Curr Protoc Cell Biol 2004, John Wiley and Sons Inc., New York, Unit 22.5. J.S. Bonifacino, M. Dasso, J.B. Harford, J. Lippincott-Schwartz, K. Yamada (Eds.).
9. Bayani J., Squire J.A. Fluorescence in situ hybridization (FISH). Curr Protoc Cell Biol 2004, John Wiley and Sons Inc., New York, Unit 22.4. J.S. Bonifacino, M. Dasso, J.B. Harford, J. Lippincott-Schwartz, K. Yamada (Eds.).
10. Bayani J., Squire J.A. Preparation of cytogenetic specimens from tissue samples. Curr Protoc Cell Biol 2004, John Wiley and Sons Inc., New York, Unit 22.2. J.S. Bonifacino, M. Dasso, J.B. Harford, J. Lippincott-Schwartz, K. Yamada (Eds.).
11. Bayani J., Zielenska M., Pandita A., Al-Romaih K., Karaskova J., Harrison K., Bridge J.A., Sorensen P., Thorner P., Squire J.A. Spectral karyotyping identifies recurrent complex rearrangements of chromosomes 8, 17, and 20 in osteosarcomas. Genes Chromosomes Cancer 2003, 36:7-16.
12. Bellacosa A., de Feo D., Godwin A.K., Bell D.W., Cheng J.Q., Altomare D.A., Wan M., Dubeau L., Scambia G., Masciullo V., Ferrandina G., Benedetti Panici P., Mancuso S., Neri G., Testa J.R. Molecular alterations of the akt2 oncogene in ovarian and breast carcinomas. Int. J. Cancer 1995, 64:280-285.
13. Blegen H., Einhorn N., Sjovall K., Roschke A., Ghadimi B.M., McShane L.M., Nilsson B., Shah K., Ried T., Auer G. Prognostic significance of cell cycle proteins and genomic instability in borderline, early and advanced stage ovarian carcinomas. Int. J. Gynecol. Cancer 2000, 10:477-487.
14. Borgono C.A., Diamandis E.P. The emerging roles of human tissue kallikreins in cancer. Nat. Rev. Cancer 2004, 4:876-890.
15. Borgono C.A., Kishi T., Scorilas A., Harbeck N., Dorn J., Schmalfeldt B., Schmitt M., Diamandis E.P. Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer. Clin. Cancer Res. 2006, 12:1487-1493.
16. Ceccaroni M., Chieco P., Alboni C., De Laco P., Pagano K., Ceccarelli C., Santini D., Taroni B., Pelusi G. P53 expression, DNA ploidy and mitotic index as prognostic factors in patients with epithelial ovarian carcinoma. Tumori 2004, 90:600-606.
17. Chow T.F., Crow M., Earle T., El-Said H., Diamandis E.P., Yousef G.M. Kallikreins as microrna targets: an in silico and experimental-based analysis. Biol. Chem. 2008, 389:731-738.
18. Day T.G., Gallager H.S., Rutledge F.N. Epithelial carcinoma of the ovary:Prognostic importance of histologic grade. Natl. Cancer Inst. Monogr. 1975, 42:15-21.
19. Diamandis E.P., Yousef G.M., Soosaipillai A.R., Grass L., Porter A., Little S., Sotiropoulou G. Immunofluorometric assay of human kallikrein 6 (zyme/protease m/neurosin) and preliminary clinical applications. Clin. Biochem. 2000, 33:369-375.
20. Etemadmoghadam D., deFazio A., Beroukhim R., Mermel C., George J., Getz G., Tothill R., Okamoto A., Raeder M.B., Harnett P., Lade S., Akslen L.A., Tinker A.V., Locandro B., Alsop K., Chiew Y.E., Traficante N., Fereday S., Johnson D., Fox S., Sellers W., Urashima M., Salvesen H.B., Meyerson M., Bowtell D. Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin. Cancer Res. 2009, 15:1417-1427.
21. Frohling S., Dohner H. Chromosomal abnormalities in cancer. N. Engl. J. Med. 2008, 359:722-734.
22. Fukasawa K. Centrosome amplification, chromosome instability and cancer development. Cancer Lett. 2005, 230:6-19.
23. Gorringe K.L., Campbell I.G. Large-scale genomic analysis of ovarian carcinomas. Mol. Oncol. 2009, 3:157-164.
24. Gorringe K.L., Chin S.F., Pharoah P., Staines J.M., Oliveira C., Edwards P.A., Caldas C. Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer. Carcinogenesis 2005, 26:923-930.
25. Gorringe K.L., Jacobs S., Thompson E.R., Sridhar A., Qiu W., Choong D.Y., Campbell I.G. High-resolution single nucleotide polymorphism array analysis of epithelial ovarian cancer reveals numerous microdeletions and amplifications. Clin. Cancer Res. 2007, 13:4731-4739.
26. Grimwood J., Gordon L.A., Olsen A., Terry A., Schmutz J., Lamerdin J., Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A., Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S., Carrano A., Caoile C., Chan Y.M., Christensen M., Cleland C.A., Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J., Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M., Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V., Leem S.H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D., McCready P., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I., Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L., Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E., Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M., Rubin E.M., Lucas S.M. The DNA sequence and biology of human chromosome 19. Nature 2004, 428:529-535.
27. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
28. Hoffman B.R., Katsaros D., Scorilas A., Diamandis P., Fracchioli S., Rigault de la Longrais I.A., Colgan T., Puopolo M., Giardina G., Massobrio M., Diamandis E.P. Immunofluorometric quantitation and histochemical localisation of kallikrein 6 protein in ovarian cancer tissue: a new independent unfavourable prognostic biomarker. Br. J. Cancer 2002, 87:763-771.
29. Inoue Y., Yokobori T., Yokoe T., Toiyama Y., Miki C., Mimori K., Mori M., Kusunoki M. Clinical significance of human kallikrein 7 gene expression in colorectal cancer. Ann. Surg. Oncol. 2010, Jun 11. [Epub ahead of print].
30. Kim H., Scorilas A., Katsaros D., Yousef G.M., Massobrio M., Fracchioli S., Piccinno R., Gordini G., Diamandis E.P. Human kallikrein gene 5 (klk5) expression is an indicator of poor prognosis in ovarian cancer. Br. J. Cancer 2001, 84:643-650.
31. Kountourakis P., Psyrri A., Scorilas A., Camp R., Markakis S., Kowalski D., Diamandis E.P., Dimopoulos M.A. Prognostic value of kallikrein-related peptidase 6 protein expression levels in advanced ovarian cancer evaluated by automated quantitative analysis (aqua). Cancer Sci. 2008, 99:2224-2229.
32. Kuo K.T., Guan B., Feng Y., Mao T.L., Chen X., Jinawath N., Wang Y., Kurman R.J., Shih Ie M., Wang T.L. Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer Res. 2009, 69:4036-4042.
33. Kyriakopoulou L.G., Yousef G.M., Scorilas A., Katsaros D., Massobrio M., Fracchioli S., Diamandis E.P. Prognostic value of quantitatively assessed klk7 expression in ovarian cancer. Clin. Biochem. 2003, 36:135-143.
34. Lai J., Myers S.A., Lawrence M.G., Odorico D.M., Clements J.A. Direct progesterone receptor and indirect androgen receptor interactions with the kallikrein-related peptidase 4 gene promoter in breast and prostate cancer. Mol. Cancer Res. 2009, 7:129-141.
35. Lassus H., Butzow R. The classification of p53 immunohistochemical staining results and patient outcome in ovarian cancer. Br. J. Cancer 2007, 96:1621-1622. Author Reply 1623-1624.
36. Lawrence M.G., Lai J., Clements J.A. Kallikreins on steroids: Structure, function, and hormonal regulation of prostate-specific antigen and the extended kallikrein locus. Endocr. Rev. 2001, 4:407-446.
37. Li L., McCormack A.A., Nicholson J.M., Fabarius A., Hehlmann R., Sachs R.K., Duesberg P.H. Cancer-causing karyotypes: chromosomal equilibria between destabilizing aneuploidy and stabilizing selection for oncogenic function. Cancer Genet. Cytogenet. 2009, 188:1-25.
38. Li X., Liu J., Wang Y., Zhang L., Ning L., Feng Y. Parallel underexpression of kallikrein 5 and kallikrein 7 mrna in breast malignancies. Cancer Sci. 2009, 100:601-607.
39. Lilja H., Ulmert D., Vickers A.J. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat. Rev. Cancer 2008, 8:268-278.
40. Maire G., Yoshimoto M., Chilton-MacNeill S., Thorner P.S., Zielenska M., Squire J.A. Recurrent recql4 imbalance and increased gene expression levels are associated with structural chromosomal instability in sporadic osteosarcoma. Neoplasia 2009, 11:260-268. 263 pp. following 268.
41. Mavridis K., Scorilas A. Prognostic value and biological role of the kallikrein-related peptidases in human malignancies. Future Oncol. 2010, 6:269-285.
42. McManus D.T., Murphy M., Arthur K., Hamilton P.W., Russell S.E., Toner P.G. P53 mutation, allele loss on chromosome 17p, and DNA content in ovarian carcinoma. J. Pathol. 1996, 179:177-182.
43. Micci F., Weimer J., Haugom L., Skotheim R.I., Grunewald R., Abeler V.M., Silins I., Lothe R.A., Trope C.G., Arnold N., Heim S. Reverse painting of microdissected chromosome 19 markers in ovarian carcinoma identifies a complex rearrangement map. Genes Chromosomes Cancer 2009, 48:184-193.
44. Nakayama K., Nakayama N., Jinawath N., Salani R., Kurman R.J., Shih Ie M., Wang T.L. Amplicon profiles in ovarian serous carcinomas. Int. J. Cancer 2007, 120:2613-2617.
45. Nakayama K., Nakayama N., Kurman R.J., Cope L., Pohl G., Samuels Y., Velculescu V.E., Wang T.L., Shih Ie M. Sequence mutations and amplification of pik3ca and akt2 genes in purified ovarian serous neoplasms. Cancer Biol. Ther. 2006, 5:779-785.
46. Nam E.J., Yoon H., Kim S.W., Kim H., Kim Y.T., Kim J.H., Kim J.W., Kim S. Microrna expression profiles in serous ovarian carcinoma. Clin. Cancer Res. 2008, 14:2690-2695.
47. Nathalie H.V., Chris P., Serge G., Catherine C., Benjamin B., Claire B., Christelle P., Briollais L., Pascale R., Marie-Lise J., Yves C. High kallikrein-related peptidase 6 in non-small cell lung cancer cells: an indicator of tumour proliferation and poor prognosis. J. Cell Mol. Med. 2009, 13:4014-4022.
48. Ni X., Zhang W., Huang K.C., Wang Y., Ng S.K., Mok S.C., Berkowitz R.S., Ng S.W. Characterisation of human kallikrein 6/protease m expression in ovarian cancer. Br. J. Cancer 2004, 91:725-731.
49. Obiezu C.V., Scorilas A., Katsaros D., Massobrio M., Yousef G.M., Fracchioli S., Rigault de la Longrais I.A., Arisio R., Diamandis E.P. Higher human kallikrein gene 4 (klk4) expression indicates poor prognosis of ovarian cancer patients. Clin. Cancer Res. 2001, 7:2380-2386.
50. Pampalakis G., Arampatzidou M., Amoutzias G., Kossida S., Sotiropoulou G. Identification and analysis of mammalian klk6 orthologue genes for prediction of physiological substrates. Comput. Biol. Chem. 2008, 32:111-121.
51. Pampalakis G., Prosnikli E., Agalioti T., Vlahou A., Zoumpourlis V., Sotiropoulou G. A tumor-protective role for human kallikrein-related peptidase 6 in breast cancer mediated by inhibition of epithelial-to-mesenchymal transition. Cancer Res. 2009, 69:3779-3787.
52. Pampalakis G., Sotiropoulou G. Multiple mechanisms underlie the aberrant expression of the human kallikrein 6 gene in breast cancer. Biol. Chem. 2006, 387:773-782.
53. Pejovic T., Heim S., Mandahl N., Baldetorp B., Elmfors B., Floderus U.M., Furgyik S., Helm G., Himmelmann A., Willen H., et al. Chromosome aberrations in 35 primary ovarian carcinomas. Genes Chromosomes Cancer 1992, 4:58-68.
54. Pejovic T., Himmelmann A., Heim S., Mandahl N., Floderus U.M., Furgyik S., Elmfors B., Helm G., Willen H., Mitelman F. Prognostic impact of chromosome aberrations in ovarian cancer. Br. J. Cancer 1992, 65:282-286.
55. Petraki C.D., Karavana V.N., Skoufogiannis P.T., Little S.P., Howarth D.J., Yousef G.M., Diamandis E.P. The spectrum of human kallikrein 6 (zyme/protease m/neurosin) expression in human tissues as assessed by immunohistochemistry. J. Histochem. Cytochem. 2001, 49:1431-1441.
56. Petraki C.D., Papanastasiou P.A., Karavana V.N., Diamandis E.P. Cellular distribution of human tissue kallikreins: immunohistochemical localization. Biol. Chem. 2006, 387:653-663.
57. Pettus J.R., Johnson J.J., Shi Z., Davis J.W., Koblinski J., Ghosh S., Liu Y., Ravosa M.J., Frazier S., Stack M.S. Multiple kallikrein (klk 5, 7, 8, and 10) expression in squamous cell carcinoma of the oral cavity. Histol. Histopathol. 2009, 24:197-207.
58. Planque C., de Monte M., Guyetant S., Rollin J., Desmazes C., Panel V., Lemarie E., Courty Y. Klk5 and klk7, two members of the human tissue kallikrein family, are differentially expressed in lung cancer. Biochem. Biophys. Res. Commun. 2005, 329:1260-1266.
59. Rao P.H., Harris C.P., Yan Lu X., Li X.N., Mok S.C., Lau C.C. Multicolor spectral karyotyping of serous ovarian adenocarcinoma. Genes Chromosomes Cancer 2002, 33:123-132.
60. Ricciardelli C., Oehler M.K. Diverse molecular pathways in ovarian cancer and their clinical significance. Maturitas 2009, 62:270-275.
61. Sadikovic B., Al-Romaih K., Squire J.A., Zielenska M. Cause and consequences of genetic and epigenetic alterations in human cancer. Curr. Genomics 2008, 9:394-408.
62. Shan S.J., Scorilas A., Katsaros D., Diamandis E.P. Transcriptional upregulation of human tissue kallikrein 6 in ovarian cancer: clinical and mechanistic aspects. Br. J. Cancer 2007, 96:362-372.
63. Shan S.J., Scorilas A., Katsaros D., Rigault de la Longrais I., Massobrio M., Diamandis E.P. Unfavorable prognostic value of human kallikrein 7 quantified by elisa in ovarian cancer cytosols. Clin. Chem. 2006, 52:1879-1886.
64. Shaw J.L., Diamandis E.P. Regulation of human tissue kallikrein-related peptidase expression by steroid hormones in 32 cell lines. Biol. Chem. 2008, 389:1409-1419.
65. Shih Ie M., Kurman R.J. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am. J. Pathol. 2004, 164:1511-1518.
66. Shinoda Y., Kozaki K., Imoto I., Obara W., Tsuda H., Mizutani Y., Shuin T., Fujioka T., Miki T., Inazawa J. Association of klk5 overexpression with invasiveness of urinary bladder carcinoma cells. Cancer Sci. 2007, 98:1078-1086.
67. Shridhar V., Lee J., Pandita A., Iturria S., Avula R., Staub J., Morrissey M., Calhoun E., Sen A., Kalli K., Keeney G., Roche P., Cliby W., Lu K., Schmandt R., Mills G.B., Bast R.C., James C.D., Couch F.J., Hartmann L.C., Lillie J., Smith D.I. Genetic analysis of early- versus late-stage ovarian tumors. Cancer Res. 2001, 61:5895-5904.
68. Sidiropoulos M., Pampalakis G., Sotiropoulou G., Katsaros D., Diamandis E.P. Downregulation of human kallikrein 10 (klk10/nes1) by cpg island hypermethylation in breast, ovarian and prostate cancers. Tumour Biol. 2005, 26:324-336.
69. Swanton C., Nicke B., Schuett M., Eklund A.C., Ng C., Li Q., Hardcastle T., Lee A., Roy R., East P., Kschischo M., Endesfelder D., Wylie P., Kim S.N., Chen J.G., Howell M., Ried T., Habermann J.K., Auer G., Brenton J.D., Szallasi Z., Downward J. Chromosomal instability determines taxane response. Proc. Natl. Acad. Sci. USA 2009, 106:8671-8676.
70. Taetle R., Aickin M., Panda L., Emerson J., Roe D., Thompson F., Davis J., Trent J., Alberts D. Chromosome abnormalities in ovarian adenocarcinoma: Ii. Prognostic impact of nonrandom chromosome abnormalities in 244 cases. Genes Chromosomes Cancer 1999, 25:46-52.
71. Taetle R., Aickin M., Yang J.M., Panda L., Emerson J., Roe D., Adair L., Thompson F., Liu Y., Wisner L., Davis J.R., Trent J., Alberts D.S. Chromosome abnormalities in ovarian adenocarcinoma: I. Nonrandom chromosome abnormalities from 244 cases. Genes Chromosomes Cancer 1999, 25:290-300.
72. Thompson F.H., Emerson J., Alberts D., Liu Y., Guan X.Y., Burgess A., Fox S., Taetle R., Weinstein R., Makar R., et al. Clonal chromosome abnormalities in 54 cases of ovarian carcinoma. Cancer Genet. Cytogenet. 1994, 73:33-45.
73. Thompson F.H., Liu Y., Emerson J., Weinstein R., Makar R., Trent J.M., Taetle R., Alberts D.S. Simple numeric abnormalities as primary karyotype changes in ovarian carcinoma. Genes Chromosomes Cancer 1994, 10:262-266.
74. Thompson F.H., Nelson M.A., Trent J.M., Guan X.Y., Liu Y., Yang J.M., Emerson J., Adair L., Wymer J., Balfour C., Massey K., Weinstein R., Alberts D.S., Taetle R. Amplification of 19q13.1-q13.2 sequences in ovarian cancer. G-band, fish, and molecular studies. Cancer Genet. Cytogenet. 1996, 87:55-62.
75. Tomasini R., Mak T.W., Melino G. The impact of p53 and p73 on aneuploidy and cancer. Trends Cell Biol. 2008, 18:244-252.
76. Tsao S.W., Wong N., Wang X., Liu Y., Wan T.S., Fung L.F., Lancaster W.D., Gregoire L., Wong Y.C. Nonrandom chromosomal imbalances in human ovarian surface epithelial cells immortalized by hpv16-e6e7 viral oncogenes. Cancer Genet. Cytogenet. 2001, 130:141-149.
77. Vojtesek B., Bartek J., Midgley C.A., Lane D.P. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J. Immunol. Methods 1992, 151:237-244.
78. Vukovic B., Beheshti B., Park P., Lim G., Bayani J., Zielenska M., Squire J.A. Correlating breakage-fusion-bridge events with the overall chromosomal instability and in vitro karyotype evolution in prostate cancer. Cytogenet. Genome Res. 2007, 116:1-11.
79. White N.M., Bui A., Mejia-Guerrero S., Chao J., Soosaipillai A., Youssef Y., Mankaruos M., Honey R.J., Stewart R., Pace K.T., Sugar L., Diamandis E.P., Dore J., Yousef G.M. Dysregulation of kallikrein-related peptidases in renal cell carcinoma: potential targets of mirnas. Biol. Chem. 2010, 391:411-423.
80. White N.M., Mathews M., Yousef G.M., Prizada A., Popadiuk C., Dore J.J. Klk6 and klk13 predict tumor recurrence in epithelial ovarian carcinoma. Br. J. Cancer 2009, 7:1107-1113.
81. Yamamoto S., Tsuda H., Honda K., Onozato K., Takano M., Tamai S., Imoto I., Inazawa J., Yamada T., Matsubara O. Actinin-4 gene amplification in ovarian cancer: a candidate oncogene associated with poor patient prognosis and tumor chemoresistance. Mod. Pathol. 2009, 22:499-507.
82. Yousef G.M., Chang A., Scorilas A., Diamandis E.P. Genomic organization of the human kallikrein gene family on chromosome 19q13.3-q13.4. Biochem. Biophys. Res. Commun. 2000, 276:125-133.
83. Yousef G.M., Polymeris M.E., Grass L., Soosaipillai A., Chan P.C., Scorilas A., Borgono C., Harbeck N., Schmalfeldt B., Dorn J., Schmitt M., Diamandis E.P. Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer. Cancer Res. 2003, 63:3958-3965.
84. Yousef G.M., Polymeris M.E., Yacoub G.M., Scorilas A., Soosaipillai A., Popalis C., Fracchioli S., Katsaros D., Diamandis E.P. Parallel overexpression of seven kallikrein genes in ovarian cancer. Cancer Res. 2003, 63:2223-2227.
85. Zhang L., Huang J., Yang N., Greshock J., Megraw M.S., Giannakakis A., Liang S., Naylor T.L., Barchetti A., Ward M.R., Yao G., Medina A., O'Brien-Jenkins A., Katsaros D., Hatzigeorgiou A., Gimotty P.A., Weber B.L., Coukos G. Micrornas exhibit high frequency genomic alterations in human cancer. Proc. Natl. Acad. Sci. USA 2006, 103:9136-9141.
86. Zhang L., Volinia S., Bonome T., Calin G.A., Greshock J., Yang N., Liu C.G., Giannakakis A., Alexiou P., Hasegawa K., Johnstone C.N., Megraw M.S., Adams S., Lassus H., Huang J., Kaur S., Liang S., Sethupathy P., Leminen A., Simossis V.A., Sandaltzopoulos R., Naomoto Y., Katsaros D., Gimotty P.A., DeMichele A., Huang Q., Butzow R., Rustgi A.K., Weber B.L., Birrer M.J., Hatzigeorgiou A.G., Croce C.M., Coukos G. Genomic and epigenetic alterations deregulate microrna expression in human epithelial ovarian cancer. Proc. Natl. Acad. Sci. USA 2008, 105:7004-7009.